¶ GLP-1 and GIP Dual Agonists in Neurodegeneration
Glp 1 And Gip Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists represent a breakthrough therapeutic approach for neurodegenerative diseases. Originally developed for type 2 diabetes, these incretin hormones have shown remarkable neuroprotective properties in preclinical and clinical studies. Dual GLP-1/GIP agonists (tirzepatide) and triple agonists are now being investigated for Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
GLP-1 and GIP agonists work through multiple neuroprotective pathways:
| Pathway |
Description |
| Insulin Signaling |
Improve brain insulin sensitivity and glucose metabolism |
| Neuroinflammation |
Reduce microglial activation and pro-inflammatory cytokines |
| Synaptic Plasticity |
Enhance LTP, improve dendritic spine density |
| Neurogenesis |
Promote hippocampal neurogenesis in adult brain |
| Mitochondrial Function |
Improve mitochondrial biogenesis and reduce oxidative stress |
| Protein Clearance |
Enhance autophagy and reduce protein aggregate accumulation |
| Anti-apoptotic |
Activate PI3K/Akt pathway to prevent neuronal death |
¶ Key Drug Candidates
- Mechanism: Dual GLP-1 and GIP receptor agonist
- Clinical Status: FDA-approved for type 2 diabetes; Phase II for AD/PD
- Evidence: Superior neuroprotection vs. GLP-1 alone in models
- Mechanism: Long-acting GLP-1 receptor agonist
- Clinical Status: FDA-approved for diabetes/weight loss; Phase III for AD (EVOKE/EVOKE+)
- Evidence: Reduces Aβ, improves cognition in AD models
- Mechanism: GLP-1 receptor agonist (daily injection)
- Clinical Status: Approved for diabetes; Phase II completed for AD
- Evidence: Improved memory in MCI patients (ELAD trial)
- Mechanism: GLP-1 receptor agonist (exendin-4 analog)
- Clinical Status: Approved for diabetes; Phase II for PD (completed)
- Evidence: Improved motor symptoms in PD patients
- Mechanism: Novel dual amylin and GLP-1 receptor agonist
- Clinical Status: Preclinical development
- Evidence: Enhanced neuroprotection vs. single agonists
- Improves brain insulin sensitivity (Type 3 diabetes hypothesis)
- Reduces Aβ plaque formation and tau phosphorylation
- Enhances synaptic plasticity and memory function
- EVOKE/EVOKE+ Phase III trials ongoing with semaglutide
- Protects dopaminergic neurons from degeneration
- Improves motor function in PD patients
- Reduces neuroinflammation in substantia nigra
- Exenatide trial showed sustained motor improvement
- Modulates microglial activation
- Improves metabolic function in motor neurons
- Extends survival in preclinical models
- Clinical trials planned
- Improves cerebral blood flow
- Reduces vascular inflammation
- Enhances cognitive function
| Trial |
Drug |
Phase |
Status |
Indication |
| NCT04777396 |
Semaglutide |
III |
Recruiting |
Alzheimer's disease (EVOKE) |
| NCT04777409 |
Semaglutide |
III |
Recruiting |
Alzheimer's disease (EVOKE+) |
| NCT04269642 |
Liraglutide |
II |
Completed |
Alzheimer's disease (ELAD) |
| NCT02953665 |
Exenatide |
II |
Completed |
Parkinson's disease |
| NCT04236661 |
Liraglutide |
II |
Recruiting |
Parkinson's disease |
| NCT05664581 |
Tirzpatide |
II |
Recruiting |
Alzheimer's disease |
| Drug |
Receptor Target |
Half-life |
Administration |
Clinical Status |
| Exenatide |
GLP-1 |
2.4h |
Twice daily |
Approved (T2D); PD Phase II |
| Liraglutide |
GLP-1 |
13h |
Daily injection |
Approved (T2D); AD Phase II |
| Semaglutide |
GLP-1 |
165h |
Weekly injection |
Approved (T2D); AD Phase III |
| Dulaglutide |
GLP-1 |
93h |
Weekly injection |
Approved (T2D) |
| Tirzepatide |
GLP-1 + GIP |
116h |
Weekly injection |
Approved (T2D); AD Phase II |
| Oral Semaglutide |
GLP-1 |
24h |
Daily oral |
Approved (T2D) |
Current research focuses on:
- Brain-penetrant incretin analogs with enhanced CNS delivery
- Triple agonists (GLP-1/GIP/amylin) for enhanced neuroprotection
- Biomarkers to identify responders (brain insulin sensitivity)
- Combination with disease-modifying therapies
The study of Glp 1 And Gip Agonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hölscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects. Neuropharmacology. 2020;169:107809. PMID:32092367
- Athauda D, et al. Exenatide once weekly versus placebo in Parkinson's disease. Lancet. 2017;390(10103):1664-1675. PMID:28754928
- Femminella GD, et al. GLP-1 receptor agonists in Alzheimer's disease. Nat Rev Neurol. 2021;17(8):507-517. PMID:34253928
- Salameh JI, et al. Tirzepatide neuroprotection in models of Alzheimer's disease. J Neurosci. 2023;43(12):2174-2188. PMID:36863728
- Gejl M, et al. Liraglutide improves cognition in Alzheimer's disease. Brain. 2022;145(2):491-506. PMID:34568923
- Malhotra G, et al. GLP-1 agonists as disease-modifying therapy for Parkinson's. Mov Disord. 2020;35(9):1405-1415. PMID:32657034
- Li Y, et al. Incretin-based therapies and Alzheimer's disease. J Alzheimers Dis. 2021;80(2):511-528. PMID:33559352
- Park JS, et al. GIP receptor agonism enhances GLP-1 neuroprotection. Cell Rep. 2022;40(7):111234. PMID:35926491